Evidence-Based GI
Multiple treatments for ulcerative colitis are now available. We look at a study published detailing a multi-center, double-blind, placebo-controlled RCT on etrasimod.
The goal of surveillance is to identify low-grade or high-grade dysplasia or early cancer at a treatable stage, however, current early cancer detection practices are ineffective. One potential explanation for these limitations is PEEC/PEEN, similar to the concept of post-colonoscopy colorectal cancer and related to endoscopy quality.
BD-IPMNs represent one of the more common types of pancreatic cystic lesions, and their surveillance entails cross-sectional imaging and/or endoscopic ultrasound. Surveillance can be offered until a patient is no longer a surgical candidate, though apart from suggestions of considering lengthening intervals if lesions are stable, there is little guidance regarding when to stop surveillance. Given the healthcare burden and cost associated with surveillance, as well as the impact on patients, studies evaluating whether and in whom surveillance can be stopped are critical.
We selected this study, which was published as a Research Letter in JAMA Medicine, because it was publicized extensively in the media. As discussed in prior summaries, the methodology of these epidemiologic reports is frequently flawed and does not confirm or even support a causal relationship between medicine and adverse event.
The New Frontier of Combination Therapy for IBD: The VEGA RCT Tarun Chhibba, MD1 and Bharati Kochar, MD, MS2 1Advanced…
In Case You Missed It Biosimilar BI 695501 Has Similar Safety and Efficacy To Adalimumab for the Treatment of Crohn’s…
Hepatitis C Virus Testing and Treatment: A Call to Action Sonali Paul, MD, MS Assistant Professor of Medicine, Division of …
Proton Pump Inhibitors Do Not Cause Dementia: Refuting Sensationalized Claims in a Post-Modern Epidemiologic Era Philip Schoenfeld, MD, MSEd, MSc…
Dr Jeff Lee provides an evidence-based summary of “Evaluating different approaches for calculating adenoma detection rate: is screening colonoscopy the gold standard?”
EBGI Associate Editor Dr Philip Okafor and Gastroparesis expert Dr Linday Nguyen provide an evidence-based review of a randomized controlled trial of efficacy and safety of cannabidiol in idiopathic and diabetic gastroparesis by Zheng T, et.